Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) saw unusually-high trading volume on Friday . Approximately 461,269 shares were traded during trading, an increase of 65% from the previous session’s volume of 278,931 shares.The stock last traded at $16.29 and had previously closed at $16.27.

AMPH has been the topic of several analyst reports. Needham & Company LLC cut their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, May 10th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. BMO Capital Markets initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, June 28th. They set a “market perform” rating and a $17.00 price target on the stock. Finally, TheStreet raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, April 14th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $16.80.

The firm has a 50-day moving average of $16.39 and a 200-day moving average of $13.53. The stock has a market cap of $725.59 million and a P/E ratio of 8090.00.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.15. The firm had revenue of $59.40 million for the quarter, compared to analyst estimates of $62 million. During the same quarter last year, the company earned ($0.01) earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Equities research analysts predict that Amphastar Pharmaceuticals Inc. will post $0.12 earnings per share for the current fiscal year.

In other Amphastar Pharmaceuticals news, President Jason B. Shandell sold 9,904 shares of the firm’s stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $16.43, for a total value of $162,722.72. Following the completion of the sale, the president now directly owns 216,610 shares in the company, valued at $3,558,902.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William J. Peters sold 2,297 shares of the firm’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $16.00, for a total transaction of $36,752.00. Following the completion of the sale, the chief financial officer now owns 66,949 shares of the company’s stock, valued at $1,071,184. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Amphastar Pharmaceuticals stock. Russell Frank Co increased its position in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) by 289.5% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 83,965 shares of the company’s stock after buying an additional 62,407 shares during the period. Russell Frank Co owned 0.19% of Amphastar Pharmaceuticals worth $1,204,000 at the end of the most recent reporting period.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.